H
Hengrui Therapeutics
Develops and commercializes drugs for oncology and endocrinology therapeutic areas
About Hengrui Therapeutics
Hengrui Therapeutics, Inc. is a Princeton, New Jersey-based biopharmaceutical company established in 2016 as the United States arm of Jiangsu Hengrui Pharmaceuticals Co., Ltd., a major Chinese pharmaceutical company. The company was launched with an initial $100 million investment arranged through HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui and an undisclosed US investment firm, with a mandate to develop and commercialize selected drug candidates from the parent company's pipeline in the United States.
The company's clinical programs focus on oncology and endocrinology, spanning immuno-oncology and metabolic disease, including drug candidates for cancer, diabetes and weight management. As a clinical-stage organization, Hengrui Therapeutics conducts US clinical development and regulatory affairs for in-licensed assets originated by its parent company.
Its business model is to in-license promising compounds from Jiangsu Hengrui's portfolio, advance them through the US regulatory pathway and, upon approval, commercialize them either directly or through partnerships with other pharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Hengrui Therapeutics in the West Windsor Township ecosystem
The Hengrui Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hengrui Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hengrui Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

